<DOC>
	<DOCNO>NCT00367224</DOCNO>
	<brief_summary>The purpose study determine vitiligo patient develop tolerance ultraviolet light therapy , type treatment available vitiligo .</brief_summary>
	<brief_title>Determining Tolerance Depigmented Skin Targeted Phototherapy Using UVB Patients With Vitiligo</brief_title>
	<detailed_description>Patients vitiligo receive 6-9 ultraviolet B treatment , 2 3 time weekly . Minimal erythema dose ( MED ) test do baseline treatment ; percent change MED analyse measure photoadaptation . The percent decrease cyclobutane pyrimidine dimer ( CPDs ) 24 hour single exposure 1 MED analyse vitiliginous normal skin .</detailed_description>
	<mesh_term>Vitiligo</mesh_term>
	<criteria>For inclusion , subject must : 1 . Be least 18 year old 2 . Be otherwise healthy 3 . Have diagnosis vitiligo affect &gt; 5 % body surface area ( BSA ) 4 . Have two depigmented lesion opposite side body biopsied end TARGETED UVB PHOTOTHERAPY treatment 5 . Agree abide Investigator 's guideline regard photosensitize drug 6 . Have negative pregnancy test baseline female childbearing potential 7 . Be able understand requirement study , risk involve , able sign inform consent form 8 . Agree follow undergo studyrelated procedure Subjects exclude follow apply : 1 . Women lactate , pregnant , plan become pregnant 2 . Patients recent history serious systemic disease 3 . Patients known history photosensitivity 4 . Concomitant use systemic topical treatment vitiligo . Patients must discontinue PUVA oral corticosteroid therapy 4 week prior start treatment . If patient take vitamin dietary supplement , patient must discontinue duration study . Topical therapy corticosteroid , topical immunomodulators ( e.g. , Protopic Elidel ) , vitamin D derivative ( e.g. , Dovonex ) , UVB phototherapy must discontinue 2 week prior start study treatment . 5 . Patients diagnose immunosuppressed reason ( e.g. , HIV infection , lupus , cancer , organ transplant , chronic use oral immunosuppressive agent ) . 6 . Any reason investigator feel patient participate study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>vitiligo</keyword>
	<keyword>tolerance</keyword>
	<keyword>ultraviolet B .</keyword>
</DOC>